Theradex was founded in 1982 with the award of the Clinical Trials Monitoring Service contract for the National Cancer Institute (NCI) in the United States. The Clinical Trial Monitoring Service provides central data management and monitoring services for early phase cancer trials sponsored by the NCI. In 2014, the services expanded to support trials conducted under the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). Theradexâ€™s support of NCI programs also includes audits of NCI-supported cancer center programs participating in NCI sponsored clinical trials. Theradexâ€™s early collaboration with NCI led to an expansion of services to pharmaceutical industry sponsored oncology clinical trials. Theradex has always recognized that each sponsor requires a personalized approach to meet their drug development and business needs. This commitment to service has supported Theradexâ€™s growth which has been primarily driven by referrals. The continued focus on personalized service has been Theradexâ€™s approach to business development. With the expansion of services to support our varied client base, the Theradex (Europe) Ltd office opened in 1992 enabling the company to expand services to Europe. Since 1992 Theradex has provided global services through partner relationships in other geographic regions including Asia. Theradex has continued to expand our capabilities by introducing efficiencies to the clinical trial process through integrated systems and expanding our expertise as personalized medicine becomes a reality. Theradex history has spanned over three decades from the early days of clinical trials with limited advances in oncology to the more rapid advances of today where pathways and patient genetic profiles are driving a targeted approach to treatment and research efforts. Our strong interest in the science of new therapeutic approaches has led Theradex to evolve with the advancements in cancer treatment. Theradex remains committed to the science of cancer research and our clients who continue to drive the advances in treatment options for cancer patients.